Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives

Insulin resistance (IR) contributes to type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Human genetics and preclinical studies link the hepatokine activin E, encoded by INHBE, and its type I receptor ALK7 to body-fat distribution, adipose lipolysis and metabolic control. Large exome-sequencing studies associate heterozygous INHBE predicted loss-of-function (pLOF) variants with lower body mass index-adjusted waist-to-hip ratio; one multi-ancestry study also reported more favorable metabolic traits and approximately 28% lower odds of T2DM. ACVR1C coding variants show similar associations, although ALK7 receives input from several ligands. Hepatocytes upregulate INHBE during non-esterified fatty-acid load and cellular stress. In mouse and adipocyte systems, secreted activin E signals through adipocyte ALK7 complexes containing ActRIIA or ActRIIB, activates SMAD2/3, and suppresses PPARγ-dependent lipolytic programs and β3-adrenergic signaling. This feedback preserves lipid stores during fasting but may promote adipocyte hypertrophy and catecholamine resistance in obesity. Lower activin E-ALK7 signaling is associated with more favorable fat distribution in human genetics, whereas reduced fat mass in mouse loss-of-function models can coexist with hepatic lipid accumulation and impaired insulin action. In one constitutive high-fat-fed mouse model, complete Inhbe loss increased hepatic lipid burden and produced a lean MASH-like phenotype. Durable efficacy and long-term hepatic safety require clinical validation. This review examines activin E biology, human genetics and preclinical evidence at three intervention levels: the activin E ligand, the ALK7 receptor and shared type II receptors, with particular attention to hepatic safety.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-17
DOI
https://doi.org/10.3389/fendo.2026.2005408
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives

Na Zhao, Zhuoshi Yang, Jian Ma
1 links
Frontiers in Endocrinology
Adipokines, Inflammation, and Metabolic Diseases
article

Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives

Na Zhao, Zhuoshi Yang, Jian Ma
article en

Abstract

Insulin resistance (IR) contributes to type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Human genetics and preclinical studies link the hepatokine activin E, encoded by INHBE, and its type I receptor ALK7 to body-fat distribution, adipose lipolysis and metabolic control. Large exome-sequencing studies associate heterozygous INHBE predicted loss-of-function (pLOF) variants with lower body mass index-adjusted waist-to-hip ratio; one multi-ancestry study also reported more favorable metabolic traits and approximately 28% lower odds of T2DM. ACVR1C coding variants show similar associations, although ALK7 receives input from several ligands. Hepatocytes upregulate INHBE during non-esterified fatty-acid load and cellular stress. In mouse and adipocyte systems, secreted activin E signals through adipocyte ALK7 complexes containing ActRIIA or ActRIIB, activates SMAD2/3, and suppresses PPARγ-dependent lipolytic programs and β3-adrenergic signaling. This feedback preserves lipid stores during fasting but may promote adipocyte hypertrophy and catecholamine resistance in obesity. Lower activin E-ALK7 signaling is associated with more favorable fat distribution in human genetics, whereas reduced fat mass in mouse loss-of-function models can coexist with hepatic lipid accumulation and impaired insulin action. In one constitutive high-fat-fed mouse model, complete Inhbe loss increased hepatic lipid burden and produced a lean MASH-like phenotype. Durable efficacy and long-term hepatic safety require clinical validation. This review examines activin E biology, human genetics and preclinical evidence at three intervention levels: the activin E ligand, the ALK7 receptor and shared type II receptors, with particular attention to hepatic safety.

Frontiers in EndocrinologyVol. 17
Heilongjiang University of Chinese Medicine (CN), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN)
Heilongjiang University of Chinese Medicine
Good health and well-being
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon